Keywords: ranbaxy, 3rd-qtr, sales, jump, laboratories, india, its
Ranbaxy's 3rd-qtr 2004 sales jump 19%
Article | 01 November 2004
Ranbaxy Laboratories of India and its subsidiaries have posted consolidated third-quarter 2004 revenues of 13.4 billion rupees ($293.9 million), rising 19% over the like, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
